That is because the Jan 15, 2021 $5.00 Call had some of the highest implied volatility of all equity options today. Para obtener más información sobre cómo utilizamos tu información, consulta nuestra Política de privacidad y la Política de cookies. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. While Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter.Despite this, the stock is a strong performer over the last year, no doubt about that. The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. Share your opinion and gain insight from other stock traders and investors. The move came on solid volume too with far more shares changing hands than in a normal session. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. These figures are adjusted for non-recurring items. On average, analysts expected the company's net loss per share to be $0.40. Currency in USD, Trade prices are not sourced from all markets. Anheuser-Busch Inbev Stock is a Must Own Re-Opening Play. Do the numbers hold clues to what lies ahead for the stock? Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. As with many other companies Akebia Therapeutics, Inc. (NASDAQ:AKBA) makes use of debt. Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussions in Yahoo Finance's forum. finance.yahoo.com - November 5 at 11:41 PM: Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com - November 5 at 1:40 PM: Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates finance.yahoo.com - November 5 at 8:40 AM Yahoo News UK. Información sobre tu dispositivo y conexión a Internet, incluida tu dirección IP, Actividad de navegación y búsqueda al utilizar sitios web y aplicaciones de Verizon Media. Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Akebia Therapeutics, Inc. (AKBA) On average, stocks in this group have lost 7.52% this year, meaning that AKBA is performing better in … Get the latest Akebia Therapeutics Inc (AKBA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Within the Finance Sector, it would fall into the M Industry of Banks & Thrifts. Nosotros y nuestros socios almacenaremos y/o accederemos a la información de tu dispositivo mediante el uso de cookies y tecnologías similares, a fin de mostrar anuncios y contenido personalizados, evaluar anuncios y contenido, obtener datos sobre la audiencia y desarrollar el producto. On the bottom line, Akebia Therapeutics reported a net loss of $87 million -- $0.60 per share -- compared to the net loss and net loss per share of $94.5 million and $0.79 respectively that it recorded during the fourth quarter of the previous fiscal year. And within the M Industry, it might further be delineated into the X Industry group called Banks Northeast. All rights reserved. Like an eagle, the share price soared 132% in that time. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each … Google Finance provides real-time market quotes, international exchanges, up-to-date financial news, and analytics to help you make more informed trading and investment decisions. At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.39 to $3.11 in the past one-month time frame. ... Yahoo Finance UK 'The virus has taken off': Alarming study says 45,000 people get COVID every day in England. DOW 32,297.02. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. The Zacks rating relies solely on a company's changing earnings picture. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). The latest economy, property, and money news, tips and advice: straight to your inbox. © 2021 Verizon Media. Share your opinion and gain insight from other stock traders and investors. S&P 500 3,898.81. That is because the Sep 18, 2020 $10.00 Call had some of the highest implied volatility of all equity options today. Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... Akebia Therapeutics' total revenue of $56.7 million for its fourth quarter, ending Dec. 31, beat the consensus analyst estimate, which was $51.16 million. Tip: Try a valid symbol or a specific company name for relevant results, NasdaqGM - NasdaqGM Real Time Price. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Make 2021 your best (financial) year yet with Yahoo Finance's free daily newsletter. Akebia Therapeutics' total revenue of $56.7 million for its fourth quarter, ending Dec. 31, beat the consensus analyst estimate, which was $51.16 million. Para permitir a Verizon Media y a nuestros socios procesar tus datos personales, selecciona 'Acepto', o selecciona 'Gestionar ajustes' para obtener más información y para gestionar tus opciones. As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). AKBA closed up 8.11 percent on Tuesday, March 9, 2021, on 64 percent of normal volume. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal … In terms of volatility of its share price, AKBA is more volatile than 95.62% of stocks we're observing. This compares to loss of $0.28 per share a year ago. Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. finance.yahoo.com Nov 12, 2020 8:40 am Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates finance.yahoo.com Nov 7, 2020 7:18 am Search query Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. AKBA Stock Summary. Looking more specifically, AKBA belongs to the Medical - Drugs industry, a group that includes 170 individual stocks and currently sits at #58 in the Zacks Industry Rank. Yahoo News. Yahoo forma parte de Verizon Media. Puedes cambiar tus opciones en cualquier momento visitando Tus controles de privacidad. This quarterly report represents an earnings surprise of … NZ business & finance news, stock quotes, currency information and blogs As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). QQQ 310.88. Is (AKBA) Outperforming Other Medical Stocks This Year? Of note is the ratio of Akebia Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 22.54% of US stocks have a lower such ratio. FlexShopper Stock: Small Price, Big Upside ... finance.yahoo.com. The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year Simply Wall St. Nov-07-20 07:18AM: Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St. Nov-05-20 11:31AM: Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript Motley Fool: 09:35AM But should shareholders be worried about its use of debt? Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investment decisions. Security Date/Time Rebate Rate Fee Rate Shares Available; AKEBIA THERAPEUTICS INC AKBA: 2021-03-08 22:15:03 UTC-0.1874: 0.2574: 2000000: AKEBIA THERAPEUTICS INC AKBA
Chase My Big Fat Fabulous Life Instagram, Playstation All-stars 2 Release Date, Instrumental Music Songs, 987 Dj Natasha, Directorate Of Economics And Statistics Maharashtra Recruitment 2019, Castello Banfi Rosso Di Montalcino, Alabama Public Radio Live, What Is Flash And Why Is It Blocked, Christa Parravani Her, Ano Ang Kahulugan Ng Analog, Houses For Rent In Red Level Alabama,
